Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jan 1;22(1):34-43.
doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J Shah  1 , Andrzej J Jakubowiak  2 , Owen A O'Connor  3 , Robert Z Orlowski  4 , R Donald Harvey  5 , Mitchell R Smith  6 , Daniel Lebovic  7 , Catherine Diefenbach  8 , Kevin Kelly  9 , Zhaowei Hua  10 , Allison J Berger  10 , George Mulligan  10 , Hélène M Faessel  10 , Stephen Tirrell  10 , Bruce J Dezube  10 , Sagar Lonial  5
Affiliations
Clinical Trial

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J Shah et al. Clin Cancer Res. .

Abstract

Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma.

Experimental design: Patients with relapsed/refractory myeloma (n = 17) or lymphoma (n = 27) received intravenous pevonedistat 25 to 147 mg/m(2) on days 1, 2, 8, 9 (schedule A; n = 27) or 100 to 261 mg/m(2) on days 1, 4, 8, 11 (schedule B; n = 17) of 21-day cycles.

Results: Maximum tolerated doses were 110 mg/m(2) (schedule A) and 196 mg/m(2) (schedule B). Dose-limiting toxicities included febrile neutropenia, transaminase elevations, muscle cramps (schedule A), and thrombocytopenia (schedule B). Common adverse events included fatigue and nausea. Common grade ≥3 events were anemia (19%; schedule A), and neutropenia and pneumonia (12%; schedule B). Clinically significant myelosuppression was uncommon. There were no treatment-related deaths. Pevonedistat pharmacokinetics exhibited a biphasic disposition phase and approximate dose-proportional increases in systemic exposure. Consistent with the short mean elimination half-life of approximately 8.5 hours, little-to-no drug accumulation in plasma was seen after multiple dosing. Pharmacodynamic evidence of NAE inhibition included increased skin levels of CDT-1 and NRF-2 (substrates of NAE-dependent ubiquitin ligases), and increased NRF-2-regulated gene transcript levels in whole blood. Pevonedistat-NEDD8 adduct was detected in bone marrow aspirates, indicating pevonedistat target engagement in the bone marrow compartment. Three lymphoma patients had partial responses; 30 patients achieved stable disease.

Conclusions: Pevonedistat demonstrated anticipated pharmacodynamic effects in the clinical setting, a tolerable safety profile, and some preliminary evidence that may be suggestive of the potential for activity in relapsed/refractory lymphoma.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest:

JJS: Consulting or Advisory Role. FORMA Therapeutics; Array BioPharma; Novartis; Celgene; Onyx; Takeda; Research Funding: Array Biopharma; Novartis; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd; Onyx; Celgene.

AJJ: Consultancy and honoraria: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Celgene, Centocor Ortho Biotech, Exelixis, Bristol-Myers Squibb, Onyx Pharmaceuticals; honoraria: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Celgene, Centocor Ortho Biotech, Exelixis, and Bristol-Myers Squibb; advisory committee member: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Centocor Ortho Biotech, Exelixis, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals.

OAO: Research funding: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Celgene, TG Therapeutics, Spectrum, Acetylon. Scientific advisory boards: Mundipharma, Novartis; TG Therapeutics.

RZO: Research funding: Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals, Resverlogix. Honoraria: Array Biopharma, Bristol-Myers Squibb, Celgene Corporation, Genentech, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals. Membership of advisory boards: Array Biopharma, Bristol-Myers Squibb, Celgene Corporation, Genentech, Merck, Millennium Pharmaceuticals, Inc., Onyx Pharmaceuticals.

RDH: Consulting or Advisory Role: BMS; Amgen; Research Funding: Eisai; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd; Onyx; Novartis; Celgene; Sanofi; AstraZeneca; Calithera Biosciences; Acetylon Pharmaceuticals; AVEO; Agensys; Merck; Genzyme; ImClone Systems; Synta; Abbott Biotherapeutics

MRS: Research funding: AbbVIE, Celgene Corporation, Janssen, Millennium Pharmaceuticals, Inc., Seattle Genetics. Membership of advisory boards: Spectrum Pharmaceuticals, Inc.

DL: no conflicts of interest to disclose.

CD: Stock or Other Ownership: Gilead Sciences; Consulting or Advisory Role: Seattle Genetics; Janssen Oncology; Idera Pharmaceuticals; Celgene; Immunogen; Speakers’ Bureau: Seattle Genetics; Gilead Sciences; Research Funding: Seattle Genetics; Genentech; Gilead Sciences; Janssen Oncology; Molecular Templates; Incyte.

KK: no conflicts of interest to disclose.

ZH, AJB, GM, HF, ST, and BJD: employees of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd

SL: Consultancy: Millennium Pharmaceuticals, Inc., Celgene, Novartis, Bristol-Myers Squibb, Onyx Pharmaceuticals, Merck.

Figures

Fig 1
Fig 1
Treatment duration with pevonedistat, by dose level and tumor type. MM and lymphoma patients received a median of 3 (range 1–9) and 3 (range 1–14) cycles, respectively. Fourteen patients (7 in each schedule) received ≥5 treatment cycles.
Fig 2
Fig 2
Mean pevonedistat plasma concentration–time profiles on (A) days 1 and 9 of schedule A, and (B) days 1 and 4 (or, alternatively, day 11) of schedule B. Mean plasma concentration–time profiles of pevonedistat exhibited a biphasic disposition phase, characterized by an initial rapid decline at the end of the infusion, followed by a slower phase with plasma concentrations remaining quantifiable up to 24 hours (schedule A) or 48 hours (schedule B) post-infusion at all doses.
Fig 3
Fig 3
Pevonedistat treatment increased CDT-1 and NRF-2 levels compared to baseline. (A) Fold-change from baseline in CDT-1 expression in skin biopsies obtained 3–6 hours after the second dose of pevonedistat in cycle 1 (day 2 on schedule A, day 4 on schedule B). (B) Representative immunohistochemistry images of skin biopsy sections stained for CDT-1 and NRF-2 taken at baseline and on cycle 1, day 2 from a patient enrolled in the 83 mg/m2 dose level on schedule A. Arrows and blue/purple staining indicate CDT-1 or NRF-2 positive staining.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 2005;12:1191–1197. - PubMed
    1. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005;12:1178–1190. - PubMed
    1. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013;13:339–358. - PubMed
    1. O'Connor OA, Wright J, Moskowitz C, Muzzy J, Gregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676–684. - PubMed
    1. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719–726. - PubMed

Publication types

MeSH terms